Immupharma Share Discussion Threads

[manual dexterity] 25/5/2022 08:07

Cash is low so they will need to raise.

[nobbygnome] 25/5/2022 07:39

So a bit more about the PK study in the results but the FDA's reasons are still not entirely clear. However, it does look like the phase III really will go ahead so the price should soar when that is announced! Then I can sell my position....

[nobbygnome] 24/5/2022 14:14

I despair…..

[lord loads of lolly] 23/5/2022 09:29

Methinks he doth protest too much.

[nobbygnome] 20/5/2022 16:00

So that LLOL actually believes me this time, I just bought a few more at 5.9 by spreadbet. Yes that is the quoted offer...

Of course it needs to be stressed again this is just a short term punt and most definitely not an investment as the management here is not to be trusted....

[mudbath] 12/5/2022 21:46

The IMM share price moves as if on a snakes and ladders board where the trades(or dice)that should determine its ascent or descent apparently having no influence.
Nevertheless, it is a great stock from which to extract a daily margin, as the MMs seem happy to part with the shares in the morning at 5.75p only to seek their return at 6p or above, after lunch.

[nobbygnome] 12/5/2022 11:08

Just checked on level 2 and as far as I can see 5.7p was offered from 8:58 to 9:07 so I was a little lucky to time it correctly!

[nobbygnome] 12/5/2022 11:06

FFS it was very easy to buy at 5.7. I did it by spreadbet; Spreadex will nearly always give you whatever the prevailing offer price is. The trade was timed at 9:04 when the offer price was 5.7 if you look back. Jeez I just can’t stand people who refuse to believe anything!

[lord loads of lolly] 12/5/2022 10:25

Given the spread, unlikely you'd have been able to BUY at 5.7p. Admittedly, the lowest trades reported by the LSE today were at 5.7p: But unless every single trade so far on 12 May was a buy, the lower prices are far more likely to have been sells.

[nobbygnome] 12/5/2022 09:08

For the record I have bought a few this morning at 5.7. Of course it's just a trade looking for a short term gain as I think the trial on the balance of probabilities will go ahead. Definitely not a long term investment though....😜

[pwhite73] 05/5/2022 15:29

No worries. In fact they've actually got two death spiral Share Agreements running with Lanstead at the same time. The one taken out on 21/12/21 that lasts for 24 months and the one still outstanding from March 2020 that comes to and end June 2022. This is a bottom drawer stock for the Phase 3 results.

RNS 21/12/2021 - "The Sharing Agreement is similar to those undertaken by the Company with Lanstead in February 2016, June 2019 and March 2020. The first two of these arrangements have completed their settlement periods. The February 2016 agreement yielded a net gain to ImmuPharma of approximately £0.6 million more than originally subscribed by Lanstead and the June 2019 agreement yielded approximately £0.9 million less than originally subscribed by Lanstead. The third arrangement runs to June 2022 and is currently yielding approximately £0.6 million less than the pro rata amount originally subscribed by Lanstead on cumulative settlements to date."

[colsmith] 05/5/2022 09:52

PW - thanks; I've just read the agreement and see that this is a good agreement if the share price is higher than benchmark but as you say the reverse is true for IMM if below, although they get something in that case.

[pwhite73] 04/5/2022 18:10

COLSMITH - "why don't they hold the stock and sell into the rise?"

They cannot do that because wherever CLNs are involved the funder can only make money when selling at prices below what PIs have bought at. This is also true for 99% of placings. If the funder holds onto the stock until it rises then they are competing with PIs and everybody else who is trading for a profit. The funder gets out at prices where you would incur a loss. That's how the system works. IMM have every financial incentive to release news that boosts the share price so Lanstead get out at higher price for their placing stock which in turn enriches IMM.

[colsmith] 04/5/2022 18:03

PW - not sure of the logic; if Lanstead sell some 92K of stock to get their cash to IMM back per month why don't they hold the stock and sell into the rise? I guess I don't know the detail of the agreement. However, I wonder if there is another reason for the low share price - such as those in the know are selling to keep the price low because on good news? as 1st in the room so to speak, they can sell and get a good gain. It seems on the surface things are going good for Lupuzor.

[pwhite73] 04/5/2022 17:47

Why would the company want to hide the clinical PK data. Unless unforgivable lies are being told we know it meets the endpoints criteria laid down by the FDA. On the back of this PK data Avion are seeking final FDA guidance on how to proceed with the Phase III study. What is the incentive to hide it when it will facilitate them getting more money from the Share Agreement with Lanstead?

[nobbygnome] 04/5/2022 17:24

I just mean wrong about the PK data. I have no doubt there will be a spike on announcement that the phase III definitely goes ahead which will allow you to get out at a profit

[pwhite73] 04/5/2022 17:16

Nobbygnome - I'm not wrong on my understanding of what's happening with the development of the lead drug however I did not realise the full implications of the Share Agreement on the share price until I checked back at the buys to sells ratio. Sells appear to be outnumbering buys for no apparent reason. Of course its the death spiral in place as IMM has no funding until Lupuzor is commercial.

[stockriser] 04/5/2022 16:49

Well at least that gap's been filled ;-)

GLA SR

[nobbygnome] 04/5/2022 16:29

It's time to admit you are wrong, pwhite. It's really not that difficult.....

As you say another spike killed no doubt by Lanstead

[pwhite73] 04/5/2022 16:02

Contrary to the RNS statements I don't believe IMM are still involved in the development of Lupuzor and this is why its going to be a major success. Avion are bearing the entire cost of the international Phase III study. They have also received strong indications from the FDA that the drug will be approved perhaps even before the end of the Phase III trial. They don't want IMM fking things up like last time. This is why I believe they are keeping the PK data close to their chests despite the agreement stating all clinical data will be shared.

IMM have been relegated to funding the directors wages by a death spiral Share Agreement. This is what is wiping out all share gains. Shareholders have to await general news Avion offers to IMM. That's my take on what's happening and in the long run its good for PIs who are prepared to bottom drawer the share.

[supernumerary] 04/5/2022 15:56

Obviously they have the results.

Wasn't there an inverse dose correlation shown at one time? That seems the most likely area of investigation for the PK study to me.

[nobbygnome] 04/5/2022 14:32

So let's think about this. IMM are planning to do another study with IMM in a different indication but are going ahead planning that without knowing the details of the PK study which are going to be critical.


It's IMM's drug FFS so they have the right to get the results.....